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Summary Epidermal growth factor receptor (EGFR) was studied in ovarian tumours with immunohis-
tochemical (IH) and ligand-binding assay (LBA). Two different monoclonal antibodies (MoAbs: 2E9, EGFR1)
with respect to detecting EGFR with different ligand-binding affinities (low, high and low) were used. When
comparing the IH data of MoAbs 2E9 and EGFR1 a significant correlation was found (2P<0.0001). Both
antibodies stained 77% of the adenocarcinoma samples. The incidence of positivity as well as the mean
percentage of stained cells was increased in metastases when compared with primary lesions. In 12.5%
overexpression of EGFR (score 3) was noticed in some of the tumour cells. This was not due to amplification
of the EGFR gene in any of the 25 ovarian tumours studied (including 6 which showed high expression of
EGFR in IH). EGFR was detected in 66% of the adenocarcinomas analysed with LBA. A statistically
significant correlation was found between the maximum binding capacities of EGFR obtained from Scatchard
plots and the percentage of positive tumour cells determined by MoAb EGFR1 (2P<0.0001). A weaker
correlation was found between the reactivity of MoAb 2E9 and LBA (2P<0.1). Clinical studies are necessary
to determine the possible prognostic impact of EGFR determined with either method, or whether a combina-
tion of both will give a better discrimination between high- and low-risk patients.
Evidence is increasing that growth factors and their receptors
are involved not only in control of normal cell growth, but
also in diseases, including cancer. The epidermal growth
factor (EGF) and its receptor (EGFR) in particular have
been investigated extensively in several tumour types. The
EGFR molecule comprises a 170 kDa membrane protein,
exhibiting an extracellular ligand (EGF or TGF-a) binding
domain, a trans-membrane region and an intracellular
domain facing the cytoplasm and exhibiting tyrosine kinase
function. In many cell types the external domain displays
high affinity (minor class) and low affinity (major class) EGF
binding sites. The high-affinity binding sites prove to be most
important for the activation ofthe signal transducing cascade
(Defize et al., 1989). Both EGF and EGFR play an essential
role in the development of mammary tissue (Tailor-Papadi-
mitriou et al., 1977). Overexpression of EGFR in human
primary breast cancer has been shown to be an indicator of a
bad prognosis with respect to both relapse-free and overall
survival (Sainsbury et al., 1987) and response to hormonal
therapy of advanced disease (Nicholson et al., 1989). How-
ever, no consensus exists regarding the prognostic
significance of EGFR (Klijn et al., 1992). With respect to the
ovary, changes in the level of EGF and EGFR in normal and
neoplastic (benign/malignant) ovarian tissue specimens and
its relation to clinical outcome have been studied less exten-
sively (Bauknecht et al., 1988, 1989, 1990; Berchuck et al.,
1991; Owens et al., 1991). In the present study we have
investigated EGFR status in ovarian tissues with immunohis-
tochemical (IH) and biochemical techniques (LBA: ligand
binding assay). The IH technique was chosen for comparison
with LBA because of its ability to identify tumour positivity
at the cellular level, even in small tumour samples, excluding
the influence of variance of tumour cellularity and the
presence of EGFR in non-tumour tissue. Moreover, two
different monoclonal antibodies (MoAbs: 2E9, EGFR1) were
used to study possible differences in staining pattern between
monoclonal antibodies reactive to different subtypes ofrecep-
tor with respect to its ligand binding affinity.
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Materials and methods
Patients
One-hundred and twenty-eight tumours (121 epithelial and 7
non-epithelial), and 21 non-tumorous ovaries were analysed.
Tumours were classifed in accordance with WHO
classification (Serov et al., 1973). Forty-six patients (mean
age 58 years) had a serous adenocarcinoma (37 primary, 9
metastatic), 20 patients (mean age 59 years) had a mucinous
adenocarcinoma (20 primary, 4 metastatic, 4 patients both), 7
patients (mean age 57 years) had an endometrioid adenocar-
cinoma (6 primary, 1 metastatic), 10 patients (mean age 56
years) had a clear-cell carcinoma (8 primary, 2 metastatic), 9
patients (mean age 54 years) had a mixed-type adenocar-
cinoma (8 primary, 3 metastatic, 2 patient both) and 8
patients (mean age 57 years) had poorly differentiated car-
cinoma (5 primary, 3 metastatic); together comprising 84
primary tumours and 22 metastases from 100 patients. From
6 patients primary as well as metastatic specimens were
available. Apart from these carcinoma patients, 9 patients
(mean age 59 years) had benign adenomas (6 serous, 3
mucinous), 9 patients (mean age 56 years) borderline malig-
nant adenomas (4 serous, 5 mucinous), 3 patients (mean age
79 years) a Brenner tumour and 7 patients (mean age 41
years) non-epithelial tumours (6 sex cord stromal tumours (3
granulosa, 3 thecoma) and one germ cell tumour (MTI)).
Immunohistochemistry
Representative tissue samples were snap-frozen in liquid nit-
rogen and stored at - 700C until use. Serial sections were cut
at a thicknes of 5 tm. These were air dried and fixed in
acetone for 10 min, after which an indirect immunoperox-
idase technique was used for visualisation of either the low
affinity binding sites with mouse IgGl MoAb 2E9 (50iLg ml-', kindly provided by Dr L.H.K. Defize, Hubrecht
Laboratory, Utrecht, The Netherlands) or the total EGF
binding sites (high and low) with mouse IgG2 MoAb
EGFR1 (50iLg ml-', Amersham, Buckinghamshire, UK) as
previously described (Henzen-Logmans et al., 1992). In all
cases sections were counterstained with Mayers haematoxylin
for 1 min. A section of normal skin was used as a positive
control. Control slides incubated with PBS and/or non-
immune ascites fluid instead of primary antibody served as
negative controls.
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Grading ofimmunohistochemical EGF-R staining
A positive or negative mark was given for epithelial (tumour)
cells only. According to the intensity of staining, results were
evaluated in grades 0 to 3. Weak but recognisable staining
was classified as grade 1, moderate as grade 2, and strong as
grade 3. When different intensities within the specimen were
noticed the highest grade was recorded. Furthermore, the
percentage of reactive cells was recorded (counting a max-
imum of 300 cells). Immunoreactivity with stromal elements
was recorded separately as either absent or present.
The average staining intensity (E score) was defined by
>_i.P(i) with summation over i= 0 - 3 (Scheres et al., 1988).
For both MoAb-2E9 and MoAb-EGFRI a highly significant
correlation was found between the E score and the percen-
tage of positive cells (Rs for MoAb-2E9 = 0.97, Rs for
MoAb-EGFRl = 0.95). In view of this strong correlation,
the easiest method to score (i.e. percentage of positive cells)
was used for further analysis.
Ligand binding assay ofEGFR
Tumour tissue was pulverized and homogenised as recom-
mended by the EORTC for processing of breast tumour
tissue for cytosolic steroid receptor determination (EORTC
Breast Cancer Cooperative Group, 1980). The homogenate
was centrifuged for 30 min at 100,000g at 4°C, and the pellet
fraction obtained was rehomogenised in 2.5 ml of buffer A
(20 mM phosphate buffer pH 7.4, containing 0.15 M NaCl
and 70 jLg ml-' Bacitracin) in an ice-bath with three 5-s
bursts at 20,000 r.p.m. of an Omni-1000 tissue homogeniser
(OMNI International, Waterbury, CT, USA). The homo-
genate was centrifuged for 10min at 1000g, and the super-
natant was defined as membrane preparation. After taking an
aliquot for membrane-protein determination, 1.1% (w/v)
bovine serum albumin (BSA, purified Behringwerke AG,
Marburg, Germany) in buffer A was added to a final concen-
tration of 0.1% (w/v) BSA. Cell membrane preparation ali-
quots of 100 jlL were incubated with eight concentrations
(ranging from 0.15 to 3.5 nM) of '25I-mEGF (mouse-EGF,
receptor grade; Bioproducts for science, Inc., Indianapolis,
IN, USA) tracer in a final volume of 140jil for 16 h at 20'C.
Non-specific binding was assessed in duplicate using 0.75 nM
'25I-mEGF and a 250-fold excess of non-labelled mEGF.
lodinated mEGF (specific activity 500-600 Ci mmol 1), pre-
pared with Protag-125 or Enzymobeads (as described in
detail by Kienhuis et al., 1991), was kindly provided by Dr
Th.J. Benraad (Sint Radboud Hospital, Nijmegen, The
Netherlands). Separation of bound and free ligand was
achieved using hydrosylapatite (essentially as described by
Benraad & Foekens, 1990) after minor modifications (Koen-
ders et al., 1991). Receptor values were calculated by Scatch-
ard analysis and expressed as fmol/mg of membrane protein.
A membrane protein threshold of 0.2 mg ml ' was adopted
to avoid possible false-negative results (Koenders et al.,
1991).
Gene amplification
For studying EGFR gene copy numbers, DNA isolated from
an aliquot of the total tissue homogenate of 25 ovarian
carcinomas was digested with either Eco RI or Hind III, size
fractioned on a 1% agarose gel and transferred to a nylon
membrane Hybond N+ (Amersham, Buckinghamshire, UK)
(Davis et al., 1986). The EGFR probe was labelled by ran-
dom primer extension (Feinberg & Vogelstein, 1983) using
32p-dATP. The filters were hybridised overnight at 65°C.
Filters were washed at high stringency (0.3 x SSC at 65C)
and autoradiographed using Kodak XAR-5 film for 1 or 5
days at - 70°C, as described before (Berns et al., 1992).
Autoradiographs were scanned with a Bio-Rad Video densi-
tometer 620. The IGF-1-receptor probe (pIGF-9-R.8, ATCC
59295) was used as a control (two gene copies) for den-
sitometry and for the amount of DNA loaded on the gel.
Statistics
Associations between groups to be compared were assessed
by the Spearman rank correlation test. Differences between
groups was tested non-parametrically by means of the Wil-
coxon two-sample test (Mann-Whitney U-test).
Results
In non-tumorous ovarian tissues (16 patients, 21 ovaries),
spindle shaped stromal cells as well as endothelial cells of
vessel walls within cortical and medullary areas often showed
immunoreactivity with MoAb-2E9 (in 15 out of 21 tissues,
71%) and MoAb-EGFRI (in 18 out of 21 tissues, 85%).
Moreover, moderate staining of surface epithelial cells was
present in four ovaries (from three patients). Corpora albi-
cantia and intercellular collagen did not stain with either
antibody. A similar pattern was noticed in the stromal com-
partment of most tumour specimens (Figure la-c). With
ligand binding assay (LBA) on membrane preparations,
EGFR was measureable by Scatchard analysis in 5 out of 11
(45%) of the non-tumorous ovarian tissues examined (range:
0-50 fmol mg membrane protein).
Table I summarises the immunohistochemical (IH) data
obtained with both MoAbs for 128 patients with an ovarian
tumour (epithelial and non-epithelial). For all tumours ana-
lysed, a significant correlation was observed between the
percentage of stained tumour cells employing MoAb-2E9 and
MoAb-EGFRI (Spearman correlation: Rs = 0.46, n = 125,
2P<0.0001). Within the tumour specimens heterogeneous
levels of expression were noticed and staining was mostly
cytoplasmic (Figure Id). If a tumour was considered positive
when one epithelial cell stained with one of the MoAbs, no
significant difference was found in the incidence of positivity
between the adenocarcinomas (primary tumours or metas-
tases) and the other 21 benign epithelial tumours (77% vs
70% positive for MoAb-2E9, and 76% vs 77% for MoAb-
EGFR1, respectively) (Table I). However, apart from one
MTI tissue with MoAb-EGFRl, the maximal intensity score
(i max; Figure Id, e) with MoAb-2E9 and/or MoAb-EGFRl
was only observed for a varying number of cells (5-80%) in
± 12.5% of the adenocarcinoma tissues (primary tumours-
+ metastases) examined (Table I). In 6 of these 13 tumour
samples with a maximal staining intensity examined, as well
as in 19 other adenocarcinomas, no amplification or rear-
rangement of the EGFR-gene was found by Southern blot
analysis. The incidence of positivity with both MoAbs was
not clearly different among the histological subtypes of the
adenocarcinomas (Table II).
In the total group of adenocarcinomas, both MoAbs gave
similar incidences of positivity, i.e. 75% positive for primary
tumours with both MoAbs, and 86% with MoAb-2E9 and
85% with MoAb-EGFRI for metastatic tumour samples
respectively (Table I). Parallel to an increased percentage of
incidence of positivity, the median level of the percentage of
stained cells was higher in the metastatic lesions as compared
with the primary tumours (for MoAb-2E9: 76% vs 36%,
2P<0.05; for MoAb-EGFRl: 67% vs 45%, 2P= 0.08)
(Table I). A similar trend was found for specimens of the
primary tumours and metastatic lesions of six patients from
whom both biopsies were obtained (Table III).
Regarding the non-epithelial tumour specimens, 3 (all
thecomas) out of 7 did not show clear expression of EGFR
with either one of the MoAbs in IH (Table I). In contrast,
EGFR was detectable in both thecomas assayed with LBA
(24 and 39 fmol mg membrane protein), as well as in high
amounts in 1 MTI and 2 granulosa cell tumours analysed
(range: 55-58 fmol mg membrane protein). For adenocar-
cinomas, there was a weak but statistically significant cor-
relation between the percentage of tumour cells stained with
MoAb-2E9 and with MoAb-EGFRI (Rs = 0.37, n = 98,
2P<0.001). With LBA and with the concentration range of
tracer used, EGFR was detectable by Scatchard analysis as a
single class of high-affinity binding sites (Kd: 0.9 ± 0.3 nM,EPIDERMAL GROWTH FACTOR RECEPTOR IN OVARIAN TUMOURS 1017
Figure 1 Non-tumorous ovarian tissue. (a) detail with surface epithelial cells and (b) spindle-shaped stromal cells and endothelial cells of vessel wall, both showing immunoreactivity for EGFR with MoAb 2E9; tumorous ovarian tissue (c) weak to moderate immunoreactivity with MoAb EGFR1 in some stromal cells and endothelial cells; serous carcinoma (d) heterogenous immunoreac- tivity for EGFR with MoAb 2E9 with cytoplasmic staining. Note the local grade 3 staining; detail of MTI (e) with grade 3 staining in epithelial cells, using MoAb EGFR1. (Indirect immunoperoxidase technique, see arrows, enlargements: a, 400 x; b, 200 x;c, 250 x; d, 400 x; e, 500 x.)1018 S.C. HENZEN-LOGMANS et al.
Table I Immunohistochemistry of EGFR in ovarian tumours
MoAb-2E9 MoAb-EGFRI
No. of Median % No. of Median %
No. of positivesl positive positivesl positive
Tumour type patients total (%) cells i-maxa total (%) cells i-max
Epithelial:
Brenner 3 2/3 (67) 95 0 3/3 (100) 96 0
Adenoma 9 6/8 (75) 70 0 6/9 (67) 40 0
Borderline 9 6/9 (67) 75 0 7/9 (78) 60 0
Carcinoma:
Primary 100 63/84 (75) 36 10 62/83 (75) 45 9
Metastasis 18/21 (86) 76 3 17/20 (85) 67c 4
Others:
MTI 1 1/1 (100) 100 0 1/1 (100) 100 I
Thecoma 3 0/3 (0) 0 0 0/3 (0) 0 0
Granulosa 3 1/3 (33) 100 0 3/3 (100) 100 0
ai-max: number of patients with maximal staining intensity (grade 3). Mann-Whitney U-test: 2P< 0.05b and 2P=0.08c.
Table H EGFR in subtypes of primary and metastatic tumours
MoAb-2E9 MoAb-EGFRJ
No. of Median % No. of Median %
Tumour type positives/ positive positives/ positive
(No. of tumours) total (%) cells i-max total (%) cells i-max
Serous
Primary (37) 28/37 (76) 45 5 30/37 (81) 40 4
Metastasis (9) 7/9 (78) 70 3 8/8 (100) 75 3
Mucinous
Primary (20) 15/20 (75) 55 2 11/15 (73) 10 I
Metastasis (4) 3/3 (100) 70 0 3/4 (75) 35 1
Endometroid
Primary (6) 5/6 (83) 55 0 6/6 (100) 52 1
Metastasis (1) 1/1 (100) 60 0 1/1 (100) 50 0
Clear cell
Primary (8) 6/8 (75) 28 0 6/8 (75) 15 l
Metastasis (2) 1/2 (50) 100 0 1/2 (50) 100 0
Mixed
Primary (8) 6/8 (75) 20 2 6/8 (75) 18 0
Metastasis (3) 3/3 (100) 60 0 2/2 (100) 52 0
Poorly differentiated:
Primary (5) 3/5 (60) 15 1 3/5 (60) 67 2
Metastastis (3) 3/3 (100) 100 0 2/3 (67) 85 0
Table HI EGFR in primary and metastatic tumours of the same patient
MoAb-2E9 MoAb-EGFRI
Patient number Percentage stained Intensity Percentage stained Intensity
and tumour type Score cells of staining Score cells of staining
1: primary-
metastasis NT'
2: primary + 60 2 + 50 1
metastasis + 70 2 + 60 3
3: primary - 10 1
metastasis + 20 1 + 50 1
4: primary + 20 1
metastasis + 90 2 + 20 1
5: primary + 100 3 + 90 2
metastasis + 60 2 NT'
6: primary
metastasis + 100 2 + 15 2
'Not tested.
mean ± s.d.) in 66% (48/73; median 17, range: 0-158 fmol
mg membrane protein) of the tumours analysed. A statis-
tically significant correlation was noted between the levels of
EGFR assessed with LBA and the percentage of stained
tumour cells determined immunohistochemically with MoAb-
EGFR1 (Rs = 0.59, n = 71, 2P<0.0001). However, the rela-
tionship between EGFR measured by LBA with that of
MoAb-2E9 was far weaker (Rs
= 0.21, n = 73, 2P<0.1).
We have subsequently chosen arbitrary cut-off points to
distinguish between EGFR-positive and -negative, in such a
way that in each case approximately two-thirds of the
tumours were positive. For these 73 adenocarcinoma biopsies
and using >0 fmol mg membrane protein as cut-offpoint for
EGFR-positivity assessed by LBA, and 10% stained cells as
cut-offpoint for IH with both MoAbs, similar percentages of
positivity were observed, i.e. 66% for LBA, 70% for MoAb-
2E9, and 66% for MoAb-EGFRl. The lowest accordance
was found for data obtained with LBA and MoAb-2E9 (45%
discordance). Data obtained with both MoAbs also showed a
relatively low accordance (34% discordance), whereas theEPIDERMAL GROWTH FACTOR RECEPTOR IN OVARIAN TUMOURS 1019
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Figure 2 Comparison ligand-binding assay with IH for EGFR with MoAb 2E9 (a) and MoAb EGFR1 (b).
accordance between data obtained with LBA and MoAb-
EGFR1 was highest (only 28% discordance). There was no
significant difference in the percentage of stained cells with
MoAb-2E9 in tumours positive or negative for EGFR as
assessed by LBA (Figure 2, left). On the other hand, the
percentage of positive tumour cells determined by IH with
MoAb-EGFRI was significantly higher in EGFR-positive
tumours assayed by LBA as compared with those which
lacked specific 251I-EGF binding (2P<0.0001; Figure 2,
right).
Discussion
This study was undertaken to investigate the correlation
between EGFR and ovarian tumour type in a series of 128
patients, using two MoAbs, one reactive to the low-affinity
ligand binding class of EGFR (MoAb-3E9), and one reactive
to both high- and low-affinity EGFR (MoAb-EGFR1), and
to compare these IH data with LBA and EGFR gene
amplification. We have shown that comparing the IH data of
MoAb-2E9 with those of MoAb-EGFRI, when applied on
all epithelial and non-epithelial tumour samples, there was a
significant correlation between the percentage of stained
tumour cells (2P<0.0001). With either MoAb, 77% of the
adenocarcinoma samples (primary and metastatic tumours)
collected from 100 patients, stained positive for EGFR. This
incidence of positivity is in agreement with the results
reported by Battaglia et al. (1989; 75% EGFR-positive in 24
cases) and by Berchuck et al. (1991; 77% EGFR-positive in
87 cases), where were obtained using LBA and IH respec-
tively, but higher than those reported by Bauknecht et al.
(1990); 50% EGFR-positive in 222 cases), who used both
techniques, and Owens et al. (1991; 39.7% EGFR-positive in
199 cases), who used LBA. The IH results in the present
study showed within-specimen heterogeneity of the levels of
expresson (from 5 to 100% of the cells). In 12.5% of the
adenocarcinomas overexpression (intensity score i max = 3)
was observed in some of the tumour cells. Overexpression of
EGFR protein might possibly be caused by amplification of
the EGFR gene. However, no EGFR gene amplification was
found in any of the 25 ovarian tumours studied, not even in
the six tumours showing high expression of EGFR protein
by IH. The absence of amplification of the EGFR gene in
ovarian tumour biopsies was also reported by Bauknecht et
al. (1990), Gullick et al. (1986), and Zhang et al. (1989).
Therefore, amplification of the EGFR gene is not likely to be
involved in ovarian carcinogenesis.
We found an increased incidence of positivity and median
percentage of stained cells in metastatic lesions, as compared
with primary tumours. Similar results were reported by Bat-
taglia et al. (1989), but these findings were not confirmed by
others (Bauknecht et al., 1990; Berchuck et al., 1991). No
significant difference was observed in the incidence of EGFR-
positivity among the histological subtypes of adeno-
carcinomas (Table II), as was also suggested before by Wit-
maack et al. (1988). In general, the staining was cytoplasmic
for both MoAbs, as has also been reported by others (Dam-
janov et al., 1986; Defize et al., 1986; Rodriquez et al., 1991;
Berchuck et al., 1991). Localisation of receptors in the cyto-
plasmic compartment may reflect internalisation of receptor,
a rapid process that occurs after ligand binding. On the other
hand, it may represent a mechanism by which postmitotic
cells maintain the capacity to bind EGF, and escape the
acute mitogenic signal in the presence of circulating EGF (or
TGF-x) (Damjanov et al., 1986).
Comparing our IH data with those of LBA on adenocar-
cinoma samples, some surprising results were obtained.
EGFR was detectable by Scatchard analysis in 66% of the
tumours analysed, and a statistically significant correlation
was found between the level determined with LBA and the
percentage of cells stained with MoAb-EGFRI (2P<
0.0001). In contrast, the relationship between biochemically
assessed EGFR and the percentage of stained tumour cells
with MoAb-2E9 was very weak (2P<0.1). When comparing
non-tumours ovarian tissues with adenocarcinomas using
LBA, the frequency of EGFR-positivity was higher in the
adenocarcinomas (66% vs 45%). This difference between the
incidence of positivity was not found when using IH with
either MoAb. Moreover, a significant number of discor-
dances was observed when comparing EGFR status as
assessed with LBA and with IH, particularly with MoAb-
2E9. This might be explained by heterogeneity of receptor
distribution in the tumour tissue. However, the low correla-
tion between LBA and IH for MoAb-2E9 is more likely to
be caused by the fact that with LBA in the concentration
range of ligand used, probably only the high-affinity class of
EGFR was determined, whereas MoAb-2E9 detects only the
low-affinity class of EGFR (Defize et al., 1989).
The 28% discordances observed between LBA and MoAb-
EGFR1 may not just be caused by heterogeneity in tissue
distribution of EGFR but also by the presence of EGFR-
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positive stromal-derived membranes, causing EGFR-positivity
in LBA and EGFR-negativity with IH using MoAb-EGFRl
when scoring only epithelial cells. This latter possibility is not
likely, as the stromal compartment of tumours which scored
positive in LBA and, negative with IH was negative for
EGFR with MoAb-EGFRl. Some of the discordances may
have been caused by the presence of receptors with an intact
antigenic site, scoring positive with IH but negative with
LBA, as they are unable to bind ligand. However, to our
knowledge no such receptors unable to bind ligand have been
described in the literature for any tumour tissue. It is impor-
tant to keep in mind that with LBA only EGFR localised in
the crude membrane preparation was determined and that
with IH cytoplasmic staining was most frequently observed
in all specimens. Thus the two techniques detect receptors at
entirely different subcellular localisations, and it may there-
fore be unrealistic to expect full concordances between LBA
and IH.
In summary, although highly significant correlations were
found between the levels of EGFR measured by LBA as
compared with the percentage of positive tumour cells stain-
ed immunohistochemically with MoAb-EGFRI, at least in
part different EGFR entities are probably determined by
both techniques. Clinical studies with the lengths of relapse-
free and overall survival as parameters are necessary to
establish the possible prognostic impact of EGFR determined
with either methodology or whether a combination of both
will give a better discrimination of high- and low-risk pa-
tients. Such a study is currently in progress.
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